The estimated Net Worth of Arnold C Hanish is at least $534 Thousand dollars as of 22 May 2023. Mr. Hanish owns over 5,000 units of Omeros stock worth over $18,400 and over the last 19 years he sold OMER stock worth over $375,493. In addition, he makes $140,170 as Independent Director at Omeros.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Hanish OMER stock SEC Form 4 insiders trading
Arnold has made over 15 trades of the Omeros stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of OMER stock worth $26,500 on 22 May 2023.
The largest trade he's ever made was buying 28,000 units of Omeros stock on 3 June 2022 worth over $5,040. On average, Arnold trades about 1,652 units every 137 days since 2005. As of 22 May 2023 he still owns at least 5,000 units of Omeros stock.
You can see the complete history of Mr. Hanish stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Arnold Hanish biography
Arnold C. Hanish is an Independent Director of Omeros Corp. He has served on our board of directors and as chairman of our audit committee since September 2012. From 1994 until his retirement in December 2012, Mr. Hanish served as vice president and chief accounting officer at Eli Lilly and Company. Prior to his appointment as chief accounting officer, Mr. Hanish held a number of senior financial positions at Eli Lilly. Before Eli Lilly, Mr. Hanish held various positions at Arthur Young & Company (currently Ernst & Young) for nearly 14 years. Mr. Hanish currently is a member of the Deloitte and Touche Audit Quality Review Council. Mr. Hanish currently serves as a member of the board of directors of Salarius Pharmaceuticals, Inc. Mr. Hanish was a member of the Standing Advisory Group of the Public Company Accounting Oversight Board from 2004 through 2008 and from 2011 through 2012. In addition, from 2007 to 2010, he served as the chairperson of Financial Executives International’s Committee on Corporate Reporting. Mr. Hanish was inducted into the Financial Executives International Hall of Fame in 2016. Mr. Hanish earned his B.A. in accounting from the University of Cincinnati. Our nominating and governance committee has concluded that Mr. Hanish should continue to serve on the board of directors based on his experience in public company finance and accounting, reporting to the U.S. Securities and Exchange Commission, or SEC, management and corporate governance, his knowledge of the pharmaceutical and biotechnology industry and his experience as the chairman of our audit committee.
What is the salary of Arnold Hanish?
As the Independent Director of Omeros, the total compensation of Arnold Hanish at Omeros is $140,170. There are 10 executives at Omeros getting paid more, with Gregory Demopulos having the highest compensation of $4,825,130.
How old is Arnold Hanish?
Arnold Hanish is 72, he's been the Independent Director of Omeros since 2012. There are 3 older and 27 younger executives at Omeros. The oldest executive at Omeros Corporation is Ray Aspiri, 83, who is the Independent Director.
What's Arnold Hanish's mailing address?
Arnold's mailing address filed with the SEC is 201 ELLIOTT AVENUE WEST, , SEATTLE, WA, 98119.
Insiders trading at Omeros
Over the last 15 years, insiders at Omeros have traded over $719,810 worth of Omeros stock and bought 141,095 units worth $829,835 . The most active insiders traders include Gregory A Md Demopulos, Marcia S. Kelbon, and Daniel K Spiegelman. On average, Omeros executives and independent directors trade stock every 53 days with the average trade being worth of $97,792. The most recent stock trade was executed by Gregory A Md Demopulos on 17 November 2023, trading 15,000 units of OMER stock currently worth $25,200.
What does Omeros do?
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
What does Omeros's logo look like?
Complete history of Mr. Hanish stock trades at Omeros, Lilly(Eli) & Co, and Salarius Pharmaceuticals
Omeros executives and stock owners
Omeros executives and other stock owners filed with the SEC include:
-
Gregory Demopulos,
Chairman of the Board, President, Chief Executive Officer -
Dr. Gregory A. Demopulos,
Co-Founder, Chairman, CEO & Pres -
Dr. Gregory A. Demopulos M.D.,
Co-Founder, Chairman, CEO & Pres -
Michael Jacobsen,
Chief Accounting Officer, Vice President - Finance, Treasurer -
Peter Cancelmo,
Vice President, General Counsel, Secretary -
Michael A. Jacobsen,
Chief Accounting Officer, VP of Fin. & Treasurer -
Peter B. Cancelmo J.D.,
VP, Gen. Counsel & Corp. Sec. -
Thomas Bumol,
Independent Director -
Thomas Cable,
Lead Independent Director -
Ray Aspiri,
Independent Director -
Arnold Hanish,
Independent Director -
Leroy Hood,
Independent Director -
Rajiv Shah,
Independent Director -
Peter Demopulos,
Director -
Kurt Zumwalt,
Independent Director -
Timothy Duffy,
Vice President - Business Development -
J. Steven Whitaker,
Vice President, Chief Medical Officer -
Tina Quinton,
Vice President - Patents -
Catherine Melfi,
Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory Officer -
Bruce Meiklejohn,
Vice President - Chemistry, Manufacturing and Controls -
Daniel Kirby,
Vice President, Chief Commercial Officer -
Christopher Bral,
Vice President - Nonclinical Development -
George Gaitanaris,
Chief Scientific Officer, Vice President - Science -
Dr. J. Steven Whitaker J.D., M.D.,
VP of Clinical Devel. & Chief Medical Officer -
Dr. Pamela Pierce Palmer M.D., Ph.D.,
Co-Founder -
Nadia Dac,
Chief Commercial Officer -
Dr. Catherine A. Melfi,
Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems -
Dr. J. Steven Whitaker,
VP of Clinical Devel. & Chief Medical Officer -
Peter W. Williams,
VP of HR -
Dr. George A. Gaitanaris M.D., Ph.D.,
Chief Scientific Officer & VP of Science -
Dr. Pamela Pierce Palmer,
Co-Founder -
Marcia S. Kelbon,
VP Patent and General Counsel -
Diana T. Perkinson,
Director -
Daniel K Spiegelman,
Director -
Jean Philippe Tripet,
Director